LivaNova PLC (LIVN)
NASDAQ: LIVN · Real-Time Price · USD
66.26
+8.67 (15.05%)
May 6, 2026, 4:00 PM EDT - Market closed
LivaNova Revenue
LivaNova had revenue of $362.26M in the quarter ending March 31, 2026, with 14.33% growth. This brings the company's revenue in the last twelve months to $1.43B, up 12.40% year-over-year. In the year 2025, LivaNova had annual revenue of $1.39B with 10.74% growth.
Revenue (ttm)
$1.43B
Revenue Growth
+12.40%
P/S Ratio
2.53
Revenue / Employee
$434,380
Employees
3,300
Market Cap
3.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.39B | 134.61M | 10.74% |
| Dec 31, 2024 | 1.25B | 99.89M | 8.66% |
| Dec 31, 2023 | 1.15B | 131.74M | 12.89% |
| Dec 31, 2022 | 1.02B | -13.56M | -1.31% |
| Dec 31, 2021 | 1.04B | 101.13M | 10.82% |
| Dec 31, 2020 | 934.24M | -149.93M | -13.83% |
| Dec 31, 2019 | 1.08B | -22.79M | -2.06% |
| Dec 31, 2018 | 1.11B | 94.68M | 9.35% |
| Dec 31, 2017 | 1.01B | 47.42M | 4.91% |
| Dec 31, 2016 | 964.86M | 673.30M | 230.93% |
| Apr 24, 2015 | 291.56M | 9.54M | 3.38% |
| Apr 25, 2014 | 282.01M | 27.69M | 10.89% |
| Apr 26, 2013 | 254.32M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bruker | 3.44B |
| Integer Holdings | 1.86B |
| Haemonetics | 1.32B |
| Neogen | 870.56M |
| iRhythm Holdings | 787.85M |
| NovoCure | 674.41M |
| TransMedics Group | 635.89M |
| UFP Technologies | 608.85M |
LIVN News
- 21 hours ago - LivaNova Earnings Call Transcript: Q1 2026 - Transcripts
- 23 hours ago - LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance - Business Wire
- 16 days ago - Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea - Business Wire
- 6 weeks ago - LivaNova to Announce First-Quarter 2026 Results - Business Wire
- 6 weeks ago - LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea - Business Wire
- 2 months ago - LivaNova Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance - Business Wire
- 3 months ago - LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results - Business Wire